Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack

ISRCTN ISRCTN66157730
DOI https://doi.org/10.1186/ISRCTN66157730
EudraCT/CTIS number 2005-003700-10
Secondary identifying numbers CL3-18886-012
Submission date
22/03/2006
Registration date
13/06/2006
Last edited
25/01/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Prof Marie-Germaine Bousser
Scientific

Hopital Lariboisiere
Service de Neurologie
2 Rue Ambroise Pare
Paris
75010
France

Study information

Study designRandomized double-blind parallel-group study
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Not specified
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titlePrevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack
Study acronymPERFORM
Study objectivesTo demonstrate the superiority of terutroban over a marketed drug (antithrombotic agent) in reducing the number of cerebrovascular and cardiovascular events in patients with cerebrovascular diseases
Ethics approval(s)First Ethics Committee approval in Italia on 06/12/2005, reference number: 42
Health condition(s) or problem(s) studiedIschaemic stroke
InterventionS 18886 (terutroban) versus antithrombotic agent
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Terutroban
Primary outcome measureCerebrovascular and cardiovascular events
Secondary outcome measuresSafety criteria
Overall study start date22/02/2006
Completion date31/03/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants18000
Key inclusion criteriaMale or female aged at least 55 years with recent history of stroke or transient ischaemic attack
Key exclusion criteriaHaemorrhagic stroke
Date of first enrolment22/02/2006
Date of final enrolment31/03/2010

Locations

Countries of recruitment

  • Austria
  • Belgium
  • Bulgaria
  • Canada
  • Chile
  • China
  • Croatia
  • Czech Republic
  • Finland
  • France
  • Greece
  • Hong Kong
  • India
  • Ireland
  • Korea, South
  • Lithuania
  • Mexico
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Portugal
  • Romania
  • Singapore
  • Slovenia
  • Sweden
  • Taiwan
  • Tunisia
  • Ukraine

Study participating centre

Hopital Lariboisiere
Paris
75010
France

Sponsor information

Institut de Recherches Internationales Servier (France)
Industry

50 rue Carnot
Suresnes
92284
France

Website http://www.servier.com/
ROR logo "ROR" https://ror.org/034e7c066

Funders

Funder type

Industry

Institut de Recherches Internationales Servier (France)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPublication plan:
All phases - Interventional studies ending before 01/10/2018: Summary results will be published on https://clinicaltrials.servier.com/ within 12 months after the end of the study.
All phases - Interventional studies ending after 01/10/2018: Summary results and a lay summary will be published on https://clinicaltrials.servier.com/ within 12 months after the end of the study.
Phase 3 only - The results will be published in scientific literature within 18 months after the end of the study.
IPD sharing planThe datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com/ if a Marketing Authorisation has been granted after 2014.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results No No
Results article results 11/06/2011 Yes No
Results article results 01/08/2014 Yes No
Results article results 01/04/2016 Yes No
Results article results 01/04/2017 Yes No

Editorial Notes

25/01/2018: Publication plan and IPD sharing statement added.
14/12/2017: results summary added. Publication reference added.
18/03/2016: Publication reference added.